Company Filing History:
Years Active: 2013-2024
Title: Jörn Lewin: Innovator in Cancer Prognosis and Diagnosis
Introduction
Jörn Lewin is a prominent inventor based in Berlin, Germany, known for his significant contributions to the field of cancer research. With a total of five patents to his name, Lewin has focused on developing methods and technologies that enhance the prognosis and diagnosis of cancer patients. His work has the potential to improve patient outcomes through more accurate detection and treatment strategies.
Latest Patents
Among his latest patents, Lewin has developed innovative methods and nucleic acids for determining the prognosis of a cancer subject. This invention provides essential tools for assessing the prognosis of individuals diagnosed with cancer. It discloses genomic sequences and methylation patterns that are crucial for the improved detection of cancer, thereby facilitating better diagnosis and treatment options for patients. Another notable patent involves methods for detecting CpG methylation and diagnosing cancer. This invention is particularly relevant in the field of pharmacogenomics, as it allows for the sensitive detection of hypermethylated DNA, which is vital for accurate cancer diagnosis.
Career Highlights
Throughout his career, Jörn Lewin has worked with several notable companies, including Epigenomics AG and New Day Diagnostics, LLC. His experience in these organizations has contributed to his expertise in cancer research and the development of diagnostic methods.
Collaborations
Lewin has collaborated with several professionals in his field, including Denise Kottwitz and Anne Schlegel. These collaborations have likely enriched his research and contributed to the advancement of cancer diagnostics.
Conclusion
Jörn Lewin's innovative work in cancer prognosis and diagnosis exemplifies the impact of scientific research on healthcare. His patents and collaborations highlight his commitment to improving cancer detection and treatment, ultimately benefiting patients worldwide.